News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Wall St. Treating Pharmaceutical IPOs Like Plague
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
The market for biomedical and pharmaceutical companies going public is sick.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
IPO
Peptide biotech Parabilis targets up to $476M IPO
June 4, 2026
·
2 min read
·
Gabrielle Masson
Deals
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets
June 4, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership
June 4, 2026
·
1 min read
·
Tristan Manalac
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
June 3, 2026
·
2 min read
·
Gabrielle Masson
